The U.S. patent application covers the design and functionality of the test device assembly, including microfluidic components, critical optical elements that hold and monitor patient microorganisms during testing, and the device’s encapsulation features.

Once granted, the U.S. patent will be valid until at least 2040. Patents within the same family are already registered in selected European countries, Japan and China.